Repair & immune · Research peptide

LL-37

Also known as cathelicidin LL-37, hCAP18-derived LL-37

A human antimicrobial peptide studied in innate immunity, inflammation, infection, and wound biology. It is not an FDA-approved drug.[1]

Compare

Prepare questions

Published evidenceMostly preclinical evidence

The evidence is mainly from cells, tissues, or animals. Any human information is limited or indirect and does not establish a clinical outcome.

U.S. status: No FDA-approved product identified
Published context: Recovery and inflammatory research
Form and route: Research LL-37 preparations · Not separately published
Main uncertainty: A central uncertainty is whether antimicrobial or repair findings translate safely to a specific human formulation and condition. Endogenous LL-37 associations should not be interpreted as evidence for administered peptide products.

Reviewed Jul 22, 2026 · U.S.-focused reference profile

Read the context, not only the compound name. Evidence and status can change with the form, route, population, and use. This profile does not assess individual suitability.

Orientation

What this is

Start with identity and research context. Similar names do not establish equivalent products or evidence.

Published name: LL-37
Type: Research peptide
Primary topic: Repair, immune, and inflammation research
Aliases: cathelicidin LL-37, hCAP18-derived LL-37

Where it has been studied or used

Published research or product contexts. These are not personal indications.

Recovery and inflammatory research

Why exact identity matters

Evidence can change with chemical form, formulation, route, ingredients, and manufacturing. A brand, salt, fragment, or cosmetic ingredient may not represent the same evidence.

What is known

Evidence, in context

Overall published evidenceMostly laboratory or animal evidence

The evidence is mainly from cells, tissues, or animals. Any human information is limited or indirect and does not establish a clinical outcome. This is a description, not a rating or recommendation.

Recovery and inflammatory research

Published human evidence context

Preclinical evidence

Human evidence includes biomarker studies and limited formulation-specific research, but it does not establish an approved therapeutic use or broad benefit from administering synthetic LL-37.

Limits and source

A central uncertainty is whether antimicrobial or repair findings translate safely to a specific human formulation and condition. Endogenous LL-37 associations should not be interpreted as evidence for administered peptide products.

LL-37

What this is

Where it has been studied or used

Evidence, in context

Published human evidence context

Risks and unknowns

Published risk information

What remains uncertain

Forms and routes

Research LL-37 preparations

U.S. status

Research only

Questions worth discussing

Sources and methodology